COVID-19 accelerated the adoption of virtual clinical trials, with 45% of sites moving to remote visits. This guide outlines eight key parameters sponsors should discuss with their CROs to evolve their technology strategy: urgency for virtualization, managing virtual consent, leveraging wearables, remote eCOA, site monitoring, centralized stats, RTSM direct-to-patient, and long-term compliance. Sponsors must adapt to evolving disruptions and regulatory demands by investing in scalable, interoperable, patient-centric technologies that reduce site burden and ensure data continuity—transforming trials beyond the pandemic into more agile, hybrid models.

Join for free to read